Abiraterone, a CYP17 inhibitor, is used in combination with prednisone in patients with metastatic Castration Resistant Prostate Cancer (mCRPC) who have received prior docetaxel chemotherapy as a third-line treatment for prostate cancer.
Specifically:
- Generally, patients with prostate cancer are sensitive to endocrine therapy in the early stages of treatment and are treated with depot therapy, which is effective.
- After a period of treatment, a proportion of patients develop hormone resistance and develop metastasis, transforming into mCRPC.
- mCRPC is not controlled after chemotherapy such as docetaxel, and can be treated with a combination of abiraterone and prednisone, which can achieve some efficacy.